Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Forte Biosciences, Inc.NASDAQ: FBRX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $19K rose 46.2% year over year, ahead of the -86.0% change in trailing-twelve-month cost of revenue.

Context

  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +46.2% holds above the trailing-twelve-month pace of -86.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19K+142.2% QoQ
Last fiscal yearDec 2025
$64K+64.1% YoY
LTMMar 2026
$6K-86.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.2%——
1 year+64.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
64K USD
Year-over-year change
+64.1%
4-year CAGR
+15.5%

Cost of Revenue vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -86.0% is the 6th highest of 8, against a peer median of -64.0%.
FBRX Competitors
Cost of Revenue for FBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M USD-62.0%-2.1%515.8%
ALECAlector, Inc.LTM Mar 2026$29.7M USD-64.0%—161.2%
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
NKTXNkarta, Inc.LTM Mar 2026$2.34M USD———
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
FBRXForte Biosciences, Inc.LTM Mar 2026$6K USD-86.0%——
ACTUActuate Therapeutics IncLTM Mar 2026$0 USD———
Peer median (excluding FBRX) —-64.0%-2.1%515.8%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue36K09K39K64K
Gross Profit(36K)0(9K)(39K)(64K)
Gross Margin—————
Research & Development13.85M5.59M21.86M21.19M58.25M
Selling, General & Admin7.63M8.3M10.62M15.37M12.41M
Operating Expenses21.49M13.9M32.48M36.56M70.66M
Depreciation & Amortization36K36K9K39K64K
EBITDA(21.67M)(13.84M)(31.47M)(35.44M)(68.27M)
EBITDA Margin—————
Operating Income(21.49M)(13.9M)(32.49M)(36.6M)(70.66M)
Operating Margin—————
Interest Income001.12M1.31M2.72M
Interest Expense00000
Other Income / Expenses(222K)17K1.01M1.12M2.32M
Income Before Tax(21.71M)(13.88M)(31.48M)(35.48M)(68.34M)
Pre-Tax Margin—————
Income Tax Expense00001.04M
Net Income(21.71M)(13.86M)(31.48M)(35.48M)(69.38M)
Net Margin—————
EPS (Basic)(38.85)(19.96)(24.92)(12.17)(4.71)
EPS (Diluted)(38.85)(19.96)(24.92)(12.17)(4.71)
Weighted Avg Shares558.71K695.34K1.26M2.92M147.18M
Weighted Avg Shares (Diluted)558.71K695.34K1.26M2.92M147.18M

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.